Academy Alumni

The Academy community

Join the community – get on the map!

Connect with other members of the European Heart Academy’s Alumni community!
To access the map, first log in to your MyESC account, then please click on the map image below.

Join now

The Alumni Task force

In 2021, the Academy’s focus is to give more opportunities to its Alumni to get involved in different activities. To identify and develop relevant projects that make sense for the entire community, a task force of 12 Alumni has been created with 4 participants from the PCHF-Zurich course, 4 participants from the MSc in Health Economics course and 4 participants from the DAS-CAM course.

Its mission is to be a link between the community and the ESC, to engage with all the Alumni and represent the Academy.

To achieve that goal, the enthusiasm of the task force has been key, in a few months of time they managed to create a momentum: mapping the alumni community, a reinforce presence on social media, include Alumni in ESC activities… and more is still to come.

We wish to create a network that really allows you to build, exchange, help you evolve in your career. The Academy and the Task force count on your interest and your support in making this community strong and influential at an individual and at a global level.

Members of the Alumni task force

International collaboration on hot topics:  HF phenotypes and Vaccination mediated peri/myocarditis 

I am a HF specialist in Reykjavík, Iceland, and I completed the PCHF 3 course in Zürich in October 2019. In the end of 2019 I constructed a prospective HF database in Iceland that includes all patients admitted with HF to the cardiology ward in Iceland. I have been gathering clinical data and QoL assessment of HF patients in a systematic way since January 1st 2020. My outline to is to start two international collaborative projects resulting in a publication with authorship:

1. Recently the ESC HF Guidelines 2021 were introduced at the ESC Congress. They reflect major advances that have taken place in the diagnosis and treatment of HF. However, some gaps in evidence still remain.  
   • Research question to answer: Further research into the underlying characteristics, pathophysiology, and diagnosis of HFmrEF and HFpEF. 
2. Iceland has one of the highest percentage of persons vaccinated for Covid-19, where 88% af the population 12 years of age and older are fully vaccinated. Myocarditis and perimyocarditis with Covid-19 mRNA vaccines has been recognized as a rare complication, especially in adolescent and young adult males.
   • Research question to answer: What is the incidence of peri/myocarditis following Covid-19 mRNA vaccines, what are the clinical findings and prognosis. For how long should these individuals be followed-up? Should these individuals avoid a potential vaccination booster later on?

For contribution and collaboration please contact:

Dr. Inga Jóna Ingimarsdóttir on ingajona@landspitali.is or ingajona@hotmail.com .

Deadline for participation: November 30th 2021.